EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis

Marcelo M Jesus iD, Daniela P Lage, Breno L Pimenta, Gabriel J L Moreira, Isabela A G Pereira, Raquel S B Câmara, Ana L Silva iD, Grasiele S V Tavares, Karolina O M Falcão iD, Saulo S G Dias, Dóris M Abrão, Maíza M Rodrigues und 8 weitere

Pathogens · 2025

DOI: 10.3390/pathogens14121202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Marcelo M Jesus und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Pesquisa do Programa de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Fede…. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Phosphorylcholine, Lipid A, Antiprotozoal Agents. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatment for visceral leishmaniasis (VL) is associated with toxicity, a high cost, and the emergence of drug-resistant parasite strains. Moreover, no human vaccine is available. In this context, immunotherapeutics combining vaccination and chemotherapy have emerged as a promising alternative. In this study, we combined a recombinant chimeric protein (ChimT) with the adjuvant 3-O-desacyl–monophosphoryl lipid A (MPLA) and the antileishmanial drug miltefosine (Milt) and used it to treat Leishmania infantum-infected mice. Parasitological, immunological, and toxicological assays were performed at 1 and 30 days post treatment. The ChimT/MPLA/Milt combination was the most effective therapeutic regimen, inducing robust Th1-type cellular and humoral immune responses, as demonstrated by increased levels of IFN-γ, IL-12, and TNF-α cytokines, nitrite, and IgG2a antibodies. These responses were associated with significant reductions in parasite load across various organs. Furthermore, the treatment showed low renal and hepatic toxicity at both evaluation time points. By contrast, ChimT alone, ChimT/MPLA, and Milt induced lower immunological and parasitological responses when compared with the ChimT/MPLA/Milt group. The results observed at 1 and 30 days post treatment demonstrated the potential of ChimT/MPLA/Milt combination against VL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, VisceralPhosphorylcholineLipid AAntiprotozoal AgentsImmunotherapyLeishmania infantumRecombinant Fusion ProteinsAnimalsMiceFemaleAntibodies, ProtozoanAdjuvants, ImmunologicMice, Inbred BALB CCytokinesDisease Models, AnimalParasite Load

Stichwörter der Autor:innen

chimeric proteinimmune responseimmunochemotherapymiltefosinemonophosphoryl lipid-Avisceral leishmaniasis

Substanzen

Phosphorylcholinemonophosphoryl lipid AmiltefosineLipid AAntiprotozoal AgentsRecombinant Fusion ProteinsAntibodies, ProtozoanAdjuvants, ImmunologicCytokines

Autor:innen und Institutionen

  • Laboratório de Pesquisa do Programa de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Avenida Alfredo Balena, 190, Belo Horizonte 30130…
  • Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35402-136, M…
  • Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo Horizonte 31270-901, Minas Gerais, Brazil.
  • Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José S/N, Umacollo, Arequipa 04000, Peru.
  • Laboratório de Biotecnologia de Microrganismos, Universidade Federal de São João Del-Rei, Divinópolis 35501-296, Minas Gerais, Brazil.
  • Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.

ORCID-Profile: Marcelo M Jesus, Ana L Silva, Karolina O M Falcão, Miguel A Chávez-Fumagalli, Bruno M Roatt, Alexsandro S Galdino, Myron Christodoulides, Camila S Freitas, Eduardo A F Coelho

Förderung

  • National Council for Scientific and Technological Development
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Brazilian agencies Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Jesus, M. M., Lage, D. P., Pimenta, B. L., Moreira, G. J. L., Pereira, I. A. G., Câmara, R. S. B., Silva, A. L., Tavares, G. S. V., Falcão, K. O. M., Dias, S. S. G., Abrão, D. M., Rodrigues, M. M., Oliveira-da-Silva, J. A., Giusta, M. S., Chávez-Fumagalli, M. A., Roatt, B. M., Galdino, A. S., Christodoulides, M., Freitas, C. S., & Coelho, E. A. F. (2025). Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis. Pathogens. https://doi.org/10.3390/pathogens14121202

Vancouver

Jesus MM, Lage DP, Pimenta BL, Moreira GJL, Pereira IAG, Câmara RSB, et al. Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis. Pathogens. 2025. doi:10.3390/pathogens14121202

BibTeX
@article{Jesus2025,
  author = {Jesus, Marcelo M and Lage, Daniela P and Pimenta, Breno L and Moreira, Gabriel J L and Pereira, Isabela A G and Câmara, Raquel S B and Silva, Ana L and Tavares, Grasiele S V and Falcão, Karolina O M and Dias, Saulo S G and Abrão, Dóris M and Rodrigues, Maíza M and Oliveira-da-Silva, João A and Giusta, Mário S and Chávez-Fumagalli, Miguel A and Roatt, Bruno M and Galdino, Alexsandro S and Christodoulides, Myron and Freitas, Camila S and Coelho, Eduardo A F},
  title = {Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14121202}
}
Kostenlos starten →